Edding Genor Group Holdings (HKSE:06998) Other Financing: HK$-213 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06998 Edding Genor Group Holdings Ltd HKSE:06998
15 GF Score
Price HK$1.53
! 1 Warning Sign
View Full Analysis

What is Edding Genor Group Holdings Other Financing?

Edding Genor Group Holdings HKSE:06998 +0.33% 15 Other Financing is HK$-213 Mil as of Dec. 2025. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Edding Genor Group Holdings's Other Financing for the six months ended in Dec. 2025 was HK$-213 Mil.

Edding Genor Group Holdings's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-213 Mil.

Edding Genor Group Holdings Other Financing Historical Data

* Premium members only.

The historical data trend for Edding Genor Group Holdings's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edding Genor Group Holdings Other Financing Chart

Edding Genor Group Holdings Annual Data
Trend Dec24 Dec25
Other Financing
-274.21 -213.16

Edding Genor Group Holdings Semi-Annual Data
Dec24 Dec25
Other Financing -274.21 -213.16
HKSE:06998
15GF Score
Edding Genor Group Holdings Ltd HKSE:06998
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edding Genor Group Holdings Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-213 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$-213 Mil mean?
Edding Genor Group Holdings (HKSE:06998) has a Other Financing of HK$-213 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Edding Genor Group Holdings and its competitors.
Is Edding Genor Group Holdings' Other Financing too high?
Edding Genor Group Holdings' current Other Financing is HK$-213 Mil. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' Other Financing compare to ZTS?
Edding Genor Group Holdings' Other Financing of HK$-213 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Edding Genor Group Holdings and its competitors. Edding Genor Group Holdings's current Other Financing is HK$-213 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current Other Financing of HK$-213 Mil. The current Other Financing is HK$-213 Mil. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current Other Financing is HK$-213 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edding Genor Group Holdings Business Description

Address No. 36 Doukou Road, Room 406, Building 1, Hengqin New Area, Guangdong Province, Zhuhai, CHN
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score

Get the complete analysis for HKSE:06998

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.53
Price